Ketoconazole is effective against the chronic mucocutaneous candidosis of autoimmune polyendocrinopathy-candidosis-ectodermal dystrophy (APECED).

Abstract

Ketoconazole was administered as a single daily oral dose of 200 mg to 12 patients with chronic mucocutaneous candidosis (CMC) of autoimmune polyendocrinopathy-candidosis-ectodermal dystrophy (APECED). The study was double-blind and placebo-controlled, with 4-month therapy periods and crossover, and transfer to open-label ketoconazole therapy in cases of failure. During the double-blind trial, all six initially ketoconazole-treated patients showed a clear clinical and mycological improvement. In contrast there was no change or worsening in the initially placebo-treated group (p = 0.001). Oral candidosis cleared up in all patients, but more rapidly (less than 2 weeks) in those aged less than 25 years than in older patients (4-10 weeks; p = 0.001). Similarly, nail candidosis improved more rapidly in the younger group. All patients had a recurrence of the candidosis during 36-48 months of post-therapy follow-up. The recurrences likewise responded to ketoconazole. In one patient serum transaminase activities were transiently and marginally elevated during 2-6 weeks of therapy.

• Authors: P Ahonen, S Myllärniemi, A Kahanpää, J Perheentupa
• Journal: Acta medica Scandinavica (Acta Med Scand) Vol. 220 Issue 4 Pg. 333-9 ( 1986) ISSN: 0001-6101 [Print] Sweden
• PMID: 3541501 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Ketoconazole

Topics

• Adolescent
• Adrenal Insufficiency (drug therapy)
• Adult
• Autoimmune Diseases (drug therapy)
• Candidiasis (drug therapy)
• Candidiasis, Chronic Mucocutaneous (drug therapy)
• Child
• Clinical Trials as Topic
• Double-Blind Method
• Ectodermal Dysplasia (drug therapy)
• Female
• Humans
• Ketoconazole (adverse effects, therapeutic use)
• Male
• Random Allocation
• Syndrome